A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this proof of mechanism pilot clinical trial is to determine if the
RXR agonist bexarotene acts in humans to alter the CSF levels of apoE and alter the clearance
of Amyloid-Beta